APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Haemophilia Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Haemophilia Treatment Market Outlook and Growth Opportunities 2026

Report ID 173996670420 December 2025197 pages

Choose your research edition.

Industry ResearchHaemophilia Treatment Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Haemophilia Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Haemophilia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Haemophilia Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Haemophilia Treatment Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Haemophilia Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Haemophilia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Haemophilia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Haemophilia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Haemophilia Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Haemophilia Treatment market include Takeda, Novo Nordisk, Roche, Pfizer, Bayer, Dimension Therapeutics, CSL Behring, Catalyst BioSciences and Aptevo Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Haemophilia Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Haemophilia Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Haemophilia Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Haemophilia Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Haemophilia Treatment Segment by Company

Takeda

Novo Nordisk

Roche

Pfizer

Bayer

Dimension Therapeutics

CSL Behring

Catalyst BioSciences

Aptevo Therapeutics

Alnylam Pharmaceuticals

Haemophilia Treatment Segment by Type

Haemophilia A

Haemophilia B

Haemophilia Treatment Segment by Application

Hospital

Pharmaceutical Companies

Other

Haemophilia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Haemophilia Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Haemophilia Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Haemophilia Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Haemophilia Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Haemophilia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Haemophilia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Haemophilia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Haemophilia Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Haemophilia Treatment industry.

Chapter 3: Detailed analysis of Haemophilia Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Haemophilia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Haemophilia Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Haemophilia Treatment Industry Trends Table 2. Haemophilia Treatment Industry Drivers Table 3. Haemophilia Treatment Industry Opportunities and Challenges Table 4. Haemophilia Treatment Industry Restraints Table 5. Global Haemophilia Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Haemophilia Treatment Revenue Share by Company (2021-2026) Table 7. Global Haemophilia Treatment Sales Volume by Company (k units) & (2021-2026) Table 8. Global Haemophilia Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Haemophilia Treatment Average Price (US$/unit) of Company (2021-2026) Table 10. Global Haemophilia Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Haemophilia Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Haemophilia Treatment Company, Product Type & Application Table 13. Global Haemophilia Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Haemophilia Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Haemophilia A Table 18. Significant Companies of Haemophilia B Table 19. Global Haemophilia Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Haemophilia Treatment Sales Volume by Type (2021-2026) & (k units) Table 21. Global Haemophilia Treatment Sales Volume by Type (2027-2032) & (k units) Table 22. Global Haemophilia Treatment Sales Volume Share by Type (2021-2026) Table 23. Global Haemophilia Treatment Sales Volume Share by Type (2027-2032) Table 24. Global Haemophilia Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Haemophilia Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Haemophilia Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Haemophilia Treatment Sales Value Share by Type (2021-2026) Table 28. Global Haemophilia Treatment Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmaceutical Companies Table 31. Significant Companies of Other Table 32. Global Haemophilia Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Haemophilia Treatment Sales Volume by Application (2021-2026) & (k units) Table 34. Global Haemophilia Treatment Sales Volume by Application (2027-2032) & (k units) Table 35. Global Haemophilia Treatment Sales Volume Share by Application (2021-2026) Table 36. Global Haemophilia Treatment Sales Volume Share by Application (2027-2032) Table 37. Global Haemophilia Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Haemophilia Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Haemophilia Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Haemophilia Treatment Sales Value Share by Application (2021-2026) Table 41. Global Haemophilia Treatment Sales Value Share by Application (2027-2032) Table 42. Global Haemophilia Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Haemophilia Treatment Sales by Region (2021-2026) & (k units) Table 44. Global Haemophilia Treatment Sales Market Share by Region (2021-2026) Table 45. Global Haemophilia Treatment Sales by Region (2027-2032) & (k units) Table 46. Global Haemophilia Treatment Sales Market Share by Region (2027-2032) Table 47. Global Haemophilia Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Haemophilia Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Haemophilia Treatment Sales Value Share by Region (2021-2026) Table 50. Global Haemophilia Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Haemophilia Treatment Sales Value Share by Region (2027-2032) Table 52. Global Haemophilia Treatment Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Haemophilia Treatment Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Haemophilia Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Haemophilia Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Haemophilia Treatment Sales by Country (2021-2026) & (k units) Table 57. Global Haemophilia Treatment Sales Market Share by Country (2021-2026) Table 58. Global Haemophilia Treatment Sales by Country (2027-2032) & (k units) Table 59. Global Haemophilia Treatment Sales Market Share by Country (2027-2032) Table 60. Global Haemophilia Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Haemophilia Treatment Sales Value Market Share by Country (2021-2026) Table 62. Global Haemophilia Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Haemophilia Treatment Sales Value Market Share by Country (2027-2032) Table 64. Takeda Company Information Table 65. Takeda Business Overview Table 66. Takeda Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Takeda Haemophilia Treatment Product Portfolio Table 68. Takeda Recent Development Table 69. Novo Nordisk Company Information Table 70. Novo Nordisk Business Overview Table 71. Novo Nordisk Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Novo Nordisk Haemophilia Treatment Product Portfolio Table 73. Novo Nordisk Recent Development Table 74. Roche Company Information Table 75. Roche Business Overview Table 76. Roche Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Roche Haemophilia Treatment Product Portfolio Table 78. Roche Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Pfizer Haemophilia Treatment Product Portfolio Table 83. Pfizer Recent Development Table 84. Bayer Company Information Table 85. Bayer Business Overview Table 86. Bayer Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Bayer Haemophilia Treatment Product Portfolio Table 88. Bayer Recent Development Table 89. Dimension Therapeutics Company Information Table 90. Dimension Therapeutics Business Overview Table 91. Dimension Therapeutics Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Dimension Therapeutics Haemophilia Treatment Product Portfolio Table 93. Dimension Therapeutics Recent Development Table 94. CSL Behring Company Information Table 95. CSL Behring Business Overview Table 96. CSL Behring Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. CSL Behring Haemophilia Treatment Product Portfolio Table 98. CSL Behring Recent Development Table 99. Catalyst BioSciences Company Information Table 100. Catalyst BioSciences Business Overview Table 101. Catalyst BioSciences Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Catalyst BioSciences Haemophilia Treatment Product Portfolio Table 103. Catalyst BioSciences Recent Development Table 104. Aptevo Therapeutics Company Information Table 105. Aptevo Therapeutics Business Overview Table 106. Aptevo Therapeutics Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Aptevo Therapeutics Haemophilia Treatment Product Portfolio Table 108. Aptevo Therapeutics Recent Development Table 109. Alnylam Pharmaceuticals Company Information Table 110. Alnylam Pharmaceuticals Business Overview Table 111. Alnylam Pharmaceuticals Haemophilia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Alnylam Pharmaceuticals Haemophilia Treatment Product Portfolio Table 113. Alnylam Pharmaceuticals Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Haemophilia Treatment Distributors List Table 117. Haemophilia Treatment Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Haemophilia Treatment Product Image Figure 2. Global Haemophilia Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Haemophilia Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Haemophilia Treatment Sales (2021-2032) & (k units) Figure 5. Global Haemophilia Treatment Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Haemophilia Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Haemophilia A Image Figure 10. Haemophilia B Image Figure 11. Global Haemophilia Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Haemophilia Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Haemophilia Treatment Sales Volume Share by Type (2021-2032) Figure 14. Global Haemophilia Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Haemophilia Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Haemophilia Treatment Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmaceutical Companies Image Figure 19. Other Image Figure 20. Global Haemophilia Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Haemophilia Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Haemophilia Treatment Sales Volume Share by Application (2021-2032) Figure 23. Global Haemophilia Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Haemophilia Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Haemophilia Treatment Sales Value Share by Application (2021-2032) Figure 26. Global Haemophilia Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Haemophilia Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Haemophilia Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Haemophilia Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Haemophilia Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. North America Haemophilia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Haemophilia Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Haemophilia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Haemophilia Treatment Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Haemophilia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Haemophilia Treatment Sales Value (2021-2032) & (US$ Million) Figure 37. South America Haemophilia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Haemophilia Treatment Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Haemophilia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Haemophilia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Haemophilia Treatment Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Haemophilia Treatment Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Haemophilia A
  • Haemophilia B
Applications
  • Hospital
  • Pharmaceutical Companies
  • Other
Companies covered
  • Takeda
  • Novo Nordisk
  • Roche
  • Pfizer
  • Bayer
  • Dimension Therapeutics
  • CSL Behring
  • Catalyst BioSciences
  • Aptevo Therapeutics
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Haemophilia Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Haemophilia Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Haemophilia Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Haemophilia Treatment Market Dynamics
  1. 2.1 Haemophilia Treatment Industry Trends
  2. 2.2 Haemophilia Treatment Industry Drivers
  3. 2.3 Haemophilia Treatment Industry Opportunities and Challenges
  4. 2.4 Haemophilia Treatment Industry Restraints
3 Haemophilia Treatment Market by Company
  1. 3.1 Global Haemophilia Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Haemophilia Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Haemophilia Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Haemophilia Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Haemophilia Treatment Company Ranking (2024-2026)
  6. 3.6 Global Haemophilia Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Haemophilia Treatment Company Product Type and Application
  8. 3.8 Global Haemophilia Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Haemophilia Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Haemophilia Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Haemophilia Treatment Market by Type
  1. 4.1 Haemophilia Treatment Type Introduction
  2. 4.1.1 Haemophilia A
  3. 4.1.2 Haemophilia B
  4. 4.2 Global Haemophilia Treatment Sales Volume by Type
  5. 4.2.1 Global Haemophilia Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Haemophilia Treatment Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Haemophilia Treatment Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Haemophilia Treatment Sales Value by Type
  9. 4.3.1 Global Haemophilia Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Haemophilia Treatment Sales Value by Type (2021-2032)
  11. 4.3.3 Global Haemophilia Treatment Sales Value Share by Type (2021-2032)
5 Haemophilia Treatment Market by Application
  1. 5.1 Haemophilia Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmaceutical Companies
  4. 5.1.3 Other
  5. 5.2 Global Haemophilia Treatment Sales Volume by Application
  6. 5.2.1 Global Haemophilia Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Haemophilia Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Haemophilia Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Haemophilia Treatment Sales Value by Application
  10. 5.3.1 Global Haemophilia Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Haemophilia Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global Haemophilia Treatment Sales Value Share by Application (2021-2032)
6 Haemophilia Treatment Regional Sales and Value Analysis
  1. 6.1 Global Haemophilia Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Haemophilia Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Haemophilia Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Haemophilia Treatment Sales by Region (2027-2032)
  5. 6.3 Global Haemophilia Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Haemophilia Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Haemophilia Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Haemophilia Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Haemophilia Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Haemophilia Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Haemophilia Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Haemophilia Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Haemophilia Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Haemophilia Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Haemophilia Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Haemophilia Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Haemophilia Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Haemophilia Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Haemophilia Treatment Sales Value Share by Country, 2025 VS 2032
7 Haemophilia Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Haemophilia Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Haemophilia Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Haemophilia Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Haemophilia Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Haemophilia Treatment Sales by Country (2027-2032)
  6. 7.4 Global Haemophilia Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Haemophilia Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Haemophilia Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Haemophilia Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Haemophilia Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Haemophilia Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Haemophilia Treatment Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Haemophilia Treatment Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Roche Haemophilia Treatment Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Haemophilia Treatment Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Haemophilia Treatment Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Dimension Therapeutics
  32. 8.6.1 Dimension Therapeutics Company Information
  33. 8.6.2 Dimension Therapeutics Business Overview
  34. 8.6.3 Dimension Therapeutics Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Dimension Therapeutics Haemophilia Treatment Product Portfolio
  36. 8.6.5 Dimension Therapeutics Recent Developments
  37. 8.7 CSL Behring
  38. 8.7.1 CSL Behring Company Information
  39. 8.7.2 CSL Behring Business Overview
  40. 8.7.3 CSL Behring Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CSL Behring Haemophilia Treatment Product Portfolio
  42. 8.7.5 CSL Behring Recent Developments
  43. 8.8 Catalyst BioSciences
  44. 8.8.1 Catalyst BioSciences Company Information
  45. 8.8.2 Catalyst BioSciences Business Overview
  46. 8.8.3 Catalyst BioSciences Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Catalyst BioSciences Haemophilia Treatment Product Portfolio
  48. 8.8.5 Catalyst BioSciences Recent Developments
  49. 8.9 Aptevo Therapeutics
  50. 8.9.1 Aptevo Therapeutics Company Information
  51. 8.9.2 Aptevo Therapeutics Business Overview
  52. 8.9.3 Aptevo Therapeutics Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Aptevo Therapeutics Haemophilia Treatment Product Portfolio
  54. 8.9.5 Aptevo Therapeutics Recent Developments
  55. 8.10 Alnylam Pharmaceuticals
  56. 8.10.1 Alnylam Pharmaceuticals Company Information
  57. 8.10.2 Alnylam Pharmaceuticals Business Overview
  58. 8.10.3 Alnylam Pharmaceuticals Haemophilia Treatment Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Alnylam Pharmaceuticals Haemophilia Treatment Product Portfolio
  60. 8.10.5 Alnylam Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Haemophilia Treatment Value Chain Analysis
  2. 9.1.1 Haemophilia Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Haemophilia Treatment Sales Mode & Process
  6. 9.2 Haemophilia Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Haemophilia Treatment Distributors
  9. 9.2.3 Haemophilia Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst